Indivior supplements merger proxy after Supernus stockholder suits; Cantor DCF values Indivior $24.20-$43.90

Indivior Pharmaceuticals, Inc.

Supernus stockholders sent demand letters and filed two complaints in NY Supreme Court alleging the joint proxy/prospectus omitted material disclosure; Supernus denies merit but supplements.
Cantor DCF reference range: Supernus $50.55-$59.50/share (9.5%-11.5% discount rate); Indivior $24.20-$43.90 dividend-adjusted (8.0%-10.0%).
Merger: Artemis Merger Sub merges into Supernus, which survives as a wholly owned Indivior subsidiary; Indivior renamed Supernus, Inc. Special stockholder votes set for October 15, 2026.
Indivior valued with ~$249M cash, ~$500M debt and a $1 billion Special Dividend; Supernus with ~$372M cash and $0 debt, using July 28, 2026 management data.
Terminal growth assumptions range from -10.0% to +3.0% after Dec 31, 2040; fully diluted Indivior share count 124.0M-139.3M.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.